Pharma Focus Asia

Boehringer Ingelheim Invests US$794 million (€700 million) in Austria

Introduction:

Boehringer Ingelheim palns for the construction of new biopharmaceutical production capacity. The new facility will be located in Austria.

Features:

The state-of-the-art facility will add a total of 185,000litres of biopharmaceutical production capacity with an additional 30 per cent in mammalian large scale capacity.

The new facility will be the most advanced one designed with high degree of digitalization and automation through smart technologies and artificial intelligence applications. In addition, multi-product plants and flexible line structures a wide variety of molecule formats, such as monoclonal antibodies, enzymes, cytokines and other recombinant proteins for patients with unmet medical needs are supplied.

The capacity is designed in a way that changes from one product to another can be done very easily in a short time or simultaneous production of different products.

After the completion of the new facility it is expected to create add 500 new jobs.

Specifications:

NameBoehringer Ingelheim
TypeNew Construction
BudgetUS$794 million (€700 million)
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Advanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024